WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
China Focus: Record Qingming holiday box office heats up for May Day moviegoing frenzyMoment So You Think You Can Dance star fears she's suffered 'acid attack'Uninsured driver, 33, who hit district judge with his car seconds before the fatherU.S. leads world in economic coercionFriendship Standing Test of Fire and BloodQiongzhou Strait faced peak of return travel during Spring Festival migrationInterview: Uncertainty to push business away from Europe, says expertCommentary: Working together for enduring ChinaInterview: Uncertainty to push business away from Europe, says expertDramatic moment carpenter, 25, who stabbed four people then murdered a Good Samaritan is arrested